In last trading session, Replimune Group Inc (NASDAQ:REPL) saw 1.52 million shares changing hands with its beta currently measuring 0.62. Company’s recent per share price level of $9.46 trading at $0.01 or 0.11% at ring of the bell on the day assigns it a market valuation of $729.24M. That closing price of REPL’s stock is at a discount of -79.7% from its 52-week high price of $17.00 and is indicating a premium of 31.92% from its 52-week low price of $6.44. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.07 million shares which gives us an average trading volume of 1.18 million if we extend that period to 3-months.
For Replimune Group Inc (REPL), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.11. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Replimune Group Inc (NASDAQ:REPL) trade information
Upright in the green during last session for gaining 0.11%, in the last five days REPL remained trading in the red while hitting it’s week-highest on Wednesday, 06/25/25 when the stock touched $9.46 price level, adding 4.73% to its value on the day. Replimune Group Inc’s shares saw a change of 7.99% in year-to-date performance and have moved -0.32% in past 5-day. Replimune Group Inc (NASDAQ:REPL) showed a performance of 12.35% in past 30-days. Number of shares sold short was 9.32 million shares which calculate 6.54 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 27 to the stock, which implies a rise of 64.96% to its current value. Analysts have been projecting 27 as a low price target for the stock while placing it at a high target of 27. It follows that stock’s current price would drop -185.41% in reaching the projected high whereas dropping to the targeted low would mean a loss of -185.41% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -14.85% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 9.79% while estimates for its earnings growth in next 5 years are of 35.14%.
Replimune Group Inc (NASDAQ:REPL)’s Major holders
Insiders are in possession of 4.51% of company’s total shares while institution are holding 107.45 percent of that, with stock having share float percentage of 112.53%. Investors also watch the number of corporate investors in a company very closely, which is 107.45% institutions for Replimune Group Inc that are currently holding shares of the company. BAKER BROS. ADVISORS LP is the top institutional holder at REPL for having 10.05 million shares of worth $90.41 million. And as of 2024-06-30, it was holding 14.5193 of the company’s outstanding shares.
The second largest institutional holder is PRICE T ROWE ASSOCIATES INC /MD/, which was holding about 9.24 million shares on 2024-06-30. The number of shares represents firm’s hold over 13.3496 of outstanding shares, having a total worth of $83.13 million.
On the other hand, T. Rowe Price New Horizons Fund, Inc. and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 4.67 shares of worth $44.14 million or 6.05% of the total outstanding shares. The later fund manager was in possession of 1.99 shares on Mar 31, 2025 , making its stake of worth around $18.81 million in the company or a holder of 2.58% of company’s stock.
